Market Overview

The Impact Of The Revolutionary I-SPY 2 TRIAL On Early Stage, High-Risk Breast Cancer Treatment: The Future Of Clinical Trials


The Impact Of The Revolutionary I-SPY 2 TRIAL On Early Stage, High-Risk Breast Cancer Treatment: The Future Of Clinical Trials

Quantum Leap Healthcare Collaborative™, sponsor of the I-SPY 2 TRIAL™, will host a press conference on September 12, 2018 at the National Press Club to update the media, patients, and the public on progress in innovative adaptive platform clinical trials that is changing the outcomes of early stage, high-risk breast cancer and advancing precision medicine.

PR Newswire

SAN FRANCISCO, Sept. 7, 2018 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announce their upcoming press conference on September 12, 2018 at the National Press Club in Washington, DC.  A press release on September 12 will precede the press event.

I-SPY TRIALs are sponsored by Quantum Leap Healthcare Collaborative (QLHC), a 501c(3) charitable organization dedicated to facilitating and accelerating the development and transfer of high-impact solutions to advance healthcare and evidence-based medicine. (PRNewsfoto/Quantum Leap Healthcare Collabo)



For almost a century, the randomized clinical trial (RCT) has been the principal tool driving the development of new and better medical treatments. However, realizing the promise of precision medicine requires a profound shift in our approach to clinical research with improved tools, new conventions for assessment, and a modernized system for approvals that ensures and enhances patient safety and minimizes toxicity. This new approach will move us from the "one drug, one trial" approach commonly used today, to a model that promotes continuous learning and improvement in outcomes.

The essential tool of this new approach is the adaptive, platform trial – a continuous, multi-treatment clinical trial model that refines the biological targeting of treatment as it learns. Although there are now a number of such trials underway, the I-SPY 2 TRIAL is one of the first, and now the longest running platform trial. It is also the most successful and the benchmark example of the power and possibilities of this new approach.

In this forum, the physicians, scientists, and regulators who are leading the charge in this revolution in clinical care and research, will describe the vision, current progress, and implications in the treatment of disease. Researchers and patients from the groundbreaking I-SPY 2 TRIAL will highlight their progress in improving outcomes for early, high-risk breast cancer and their plans to further positively disrupt the clinical trial space.

Following the forum, members of the press are invited to a seminar designed for science writers to provide additional detail and answer questions.


Key speakers include: Dr. Laura Esserman, Founder and Co-Principal Investigator of the I-SPY Trials; Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research, FDA; Dr. Anna D Barker, Co-director, Complex Adaptive Systems—Biomedicine, and Director of Transformative Healthcare Networks at Arizona State University; and Dr. Donald A Berry, I-SPY 2 Co-Principal Investigator and lead statistician of Berry Consultants.


Wednesday, September 12, 2018

Press Briefing:  2:00-3:40 pm ET (light lunch at 12:45 pm ET)

Science writer seminar: 3:45-5:00 pm ET


The National Press Club | 529 4th St, NW, 13th Floor | Washington, DC


Kristen Zeitzer

Director of Marketing and Communications

Quantum Leap Healthcare Collaborative

(415) 215-6893;

About Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative (QLHC) is a 501C(3) charitable organization established in 2005 as a collaboration between medical researchers at University of California, San Francisco and Silicon Valley entrepreneurs. Our mission is to integrate high-impact research with clinical processes and systems technology, resulting in improved data management and information systems, greater access to clinical trial matching and sponsorship, and greater benefit to providers, patients and researchers. Our goal is to improve and save lives. Quantum Leap provides operational, financial, and regulatory oversight to I-SPY. For more information, visit


The I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) is squarely focused on early stage breast cancers that have a high risk of recurrence. (PRNewsfoto/Quantum Leap Healthcare Collabo)

Cision View original content with multimedia:

SOURCE Quantum Leap Healthcare Collaborative

View Comments and Join the Discussion!